As advised via Pharmac Tender announcement 28 April 2017 there is to be a change in the listing and future sole supply.

New listing from 1 November 2017

Simvastatin-Mylan Tab 10 mg 90          Pharmacode  2520087                              Schedule price $0.95

Simvastatin-Mylan Tab 20 mg 90          Pharmacode  2520095                              Schedule price $1.52

Simvastatin-Mylan Tab 40 mg 90          Pharmacode  2520109                              Schedule price $2.63

Simvastatin-Mylan Tab 80 mg 90          Pharmacode  2520117                              Schedule price $6.00

Incumbent brand

Simva-Arrow Tab 10 mg 90                    Pharmacode  2316668                  Schedule price $0.95

Simva-Arrow Tab 20 mg 90                    Pharmacode  2316676                  Schedule price $1.61

Simva-Arrow Tab 40 mg 90                    Pharmacode  2316684                  Schedule price $2.83

Simva-Arrow Tab 80 mg 90                    Pharmacode  2316692                  Schedule price $7.91

Reference pricing has been deferred until further notice (was to be 1 January 2018)

STAT  Dispensing will formally be removed and dispensing in one month lots is recommended.

We recommend you continue to purchase the incumbent and we will change automatically as existing stocks are depleted.

Click here to read the PHARMAC Dispatch from 21 December 2017

Benefit of staying with incumbent

In association with Actavis pricing was reduced significantly from 2 October 2017. Allocations have been removed.

Click here to review the Simvastatin $$ Analysis

These additional margin gains may appear minimal but on volume they are significant.

Click here to access the Simvastatin Mylan Tablet Description & Dimensions. Mylan stock has now been received at Mylan and will be distributed to wholesalers as soon as practical.

Once again we need your support to ensure stock in the supply chain moves through to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author